The FOURIER trial suggests again the lower the cholesterol the better!

Dr Malik says:
Statins are good news: One third reduction in cholesterol; One third reduction in risk.
If you can’t tolerate them, then fibrates, ezetimibe,  and other drugs do not have the same level of evidence.
The FOURIER Trial now suggests that, even in a background of statin therapy, you get 50-60% more reduction in cholesterol, and about 15% more reduction in risk, all be it with an injection every few weeks.
It involved over 27,000 patients over 2.2 years. In such a short term me, it is impressive that any difference in hard cardiovascular outcomes was actually seen. Heart attack, stroke and revascularisation rates all when down.
Worth thinking about!
Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9)
Posted on 26 March 2017
Author: LCC

Cardiology Information

View all